Therefore, elucidating the complex mechanisms of the immune microenvironment of HCC, rather than simply inhibiting angiogenesis through VEGF inhibition, may lead to the development of therapeutic targets and the overcoming of treatment resistance. Here, VEGFA is linked to hepatocellular carcinoma.